OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.260
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Updated Efficacy of Avelumab in Patients With Previously Treated Metastatic Merkel Cell Carcinoma After ≥1 Year of Follow-Up: JAVELIN Merkel 200, a Phase 2 Clinical Trial

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

KEYNOTE-045: Randomized Phase 3 Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Metastatic Urothelial Cancer.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Gefitinib Versus Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (Nsclc): A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Atezolizumab in Japanese Patients With Previously Treated, Advanced Non–small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

Pcn176 - A Cost-Effectiveness Analysis of Atezolizumab Versus Docetaxel for Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Belgium

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P3.04-17 Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA10 CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy